Amrita Institute of Medical Sciences Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2006
NCT00299195
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Amrita Institute of medical sciences and research Center kochi | Amrita Institute of Medical Sciences, Kochi | Amrita Institute of Medical Sciences & Research Center | Amrita Institute of Sciences, AIMS, Cochin, India

Active Ingredients

Drugs in Phase 4 Trials (1)

insulin glargine (toujeo) (1 trial)

Drugs in Phase 3 Trials (1)

cisplatin (platinol) (1 trial)

Drugs in Phase 2 Trials (4)

arhalofenate (1 trial)

autologous mesenchymal stem cells (1 trial)

pioglitazone (actos) (1 trial)

sitagliptin (januvia) (1 trial)

Drugs in Other Trials (1)

sulindac (clinoril) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Diabetic Foot (Phase 4)

Foot Ulcer (Phase 4)

Ischemia (Phase 2)

Ulcer (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 7